Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDI...
Publications
View AllInstitution Info
- Type
- nonprofit
- Country
- DE
- Publications
- 1
- Citations
- 1,012
External Links
Identifiers
- ROR
- https://ror.org/024f43q37